Capital Health joins Kiyatec’s clinical trial to validate a patient-specific predictor test to improve response to cancer therapies for glioblastoma and anaplastic astrocytoma.
Sartorius Stedim Biotech (SSB) has cut its full year guidance, citing the negative impact of hurricane Maria, customer destocking and ongoing issues with a cell culture media supplier.